AVA 203
Alternative Names: AVA-203; AVA-203-Avalon GloboCare; MSC-Exosome derived AVA-203Latest Information Update: 28 Aug 2023
At a glance
- Originator Avalon GloboCare
- Class Antifibrotics; Exosome therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatic fibrosis; Pulmonary fibrosis
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for preclinical development in Hepatic-fibrosis in USA (IV, Injection)
- 28 Aug 2023 No recent reports of development identified for preclinical development in Pulmonary-fibrosis in USA (IV, Injection)
- 24 Jul 2019 Preclinical trials in Hepatic fibrosis in USA (IV) (Avalon GloboCare pipeline, July 2019)